Clinical Trial Update: Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating repurposed fenofibrate to modulate mTOR/NLRP3 inflammasome in ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: Tanta University | Conditions: Inflammatory Bowel Diseases | Phase 2 | Status: COMPLETED